Chronic Stress
Activates the HPA axis, driving sustained cortisol release, eroding sleep, immunity, and energy.
The Hidden Spiral Your Body Can't Escape
Chronic stress and gut imbalance fuel each other. Single-ingredient solutions break only one arm of the cycle.
Gut Disruption
Cortisol shifts gut composition: beneficial bacteria decline, harmful pathogens expand.
Gut, Stress, Brain Feedback
A dysbiotic gut signals back to the brain, amplifying HPA tone the spiral continues. .
Most Solutions Fix Only One Arm
Callout: No mainstream ingredient recalibrates the HPA axis and selectively restores microbiome balance in a single dose. ThymoQuin does it all - at a 500 mg/day dose.
| Approach | What it targets | What it misses |
|---|---|---|
| Adaptogens (ashwagandha, rhodiola) | Primarily HPA axis and cortisol | The gut root cause + mood signaling |
| Probiotics | Gut microbiome | The stress response + mood signaling |
| Mood supplements (5-HTP, SAMe) | Brain neurotransmitters | The upstream gut and cortisol signals |
| ThymoQuin® | All three: HPA, microbiome, and the immune-neural network that connects them | Nothing |
Three Converging Pathways
-
Anti-Inflammatory & Mitochondrial
Inhibits NF-κB, TNF-α, and COX. Supports mitochondrial function and lowers oxidative stress.
-
Selective Microbiome Modulation
Amplifies beneficial commensals and suppresses pathogens within a precise hormetic window. Supports the neural signaling that reaches the brain.
-
HPA-Axis Recalibration
Sustained thymoquinone exposure restores cortisol-DHEA balance, sleep and mood, through the same gut-brain-immune communication network that connects the microbiome to psychological and physiological well-being.
Eight Headline Outcomes. Four Studies. One Dose.
All outcomes measured at 500 mg/day, across 4 to 8 weeks of daily supplementation.
↓ 23-44%
Cortisol Reduction
↑ 29%
DHEA : Cortisol Ratio
(verified stress resilience adaptogenic signature)
53×
Beneficial Gut Bacteria
(S. thermophilus)
> 94%
Harmful Pathogen Suppression
(K. pneumoniae)
62%
Fewer Illness Episodes
(URTCs)
↑ 31%
Sleep Quality Improvement
↑ 11-27%
Mood Improvement
(POMS across Talbott 2022 and 2026)
> 94%
Harmful Pathogen Suppression
(K. pneumoniae)
In vitro · 0.125–0.5% concentration window
A Hormetic Window, Not a Sledgehammer
In vitro research shows ThymoQuin operates within a defined concentration window (0.125 to 0.5%) where it amplifies beneficial bacteria and reduces opportunistic pathogens simultaneously. Outside this window, selectivity is lost. ThymoQuin is standardized to ≥3% thymoquinone, with less than 1.25% free fatty acids. This is a precision only ThymoQuin can deliver and its 500 mg/day dose.
S. thermophilus
↑ 53×
L. plantarum preserved
~
A. muciniphila tolerated
~
K. pneumoniae
↓ >94%
≥3%
Thymoquinone
<1.25%
Free fatty acids
500 mg
Per day
When the Axis Balances, Everything Follows:
Cortisol, Sleep, Mood, and Beyond
- Verified adaptogenic signature – cortisol down and DHEA up simultaneously
- 10× stress resilience index vs. placebo (Talbott 2026)
- 31% sleep quality improvement (Talbott 2026)
- Measurable mood improvement – +11% POMS (Talbott 2022), +27% POMS Vigor (Talbott 2026)
- Stress resilience via the gut-stress conversation – the same microbial shift that improves microbial balance feeds directly into the neural network that shapes mood, psychological and physiological wellbeing
- 62% fewer upper-respiratory episodes (Talbott 2022)
- Cardiovascular support – 11.2% systolic and 12.2% diastolic BP reduction (Bush et al., 2020)
Formulating for the Full Gut-Stress Axis?
At 500 mg/day, ThymoQuin® is the only clinically studied ingredient shown to dually support HPA-axis regulation and selectively rebalance the gut microbiome two key pathways in the gut–stress axis.
Our team can help you position it in stress, sleep, mood, gut, metabolic, and/or multi-benefits formulations.
*These statements have not been evaluated by the FDA. ThymoQuin is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting a new supplement.
